The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

Abstract High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, h...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Yongfeng Wu, Jinming Xu, Jiawei Xu, Yiqing Wang, Luming Wang, Wang Lv, Jian Hu
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2020-04-01
Rangatū:	Biomarker Research
Ngā marau:	Tumor mutation burden TMB Age Immune checkpoint inhibitor ICI NSCLC
Urunga tuihono:	http://link.springer.com/article/10.1186/s40364-020-00188-2
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!